PE20070707A1 - Compuestos de tetrahidro-pirrolizinona como inhibidores de lfa-1 - Google Patents

Compuestos de tetrahidro-pirrolizinona como inhibidores de lfa-1

Info

Publication number
PE20070707A1
PE20070707A1 PE2006001210A PE2006001210A PE20070707A1 PE 20070707 A1 PE20070707 A1 PE 20070707A1 PE 2006001210 A PE2006001210 A PE 2006001210A PE 2006001210 A PE2006001210 A PE 2006001210A PE 20070707 A1 PE20070707 A1 PE 20070707A1
Authority
PE
Peru
Prior art keywords
alkyl
compounds
alkynyl
aryl
substituted
Prior art date
Application number
PE2006001210A
Other languages
English (en)
Inventor
Karl Baumann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0520376.5A external-priority patent/GB0520376D0/en
Priority claimed from GB0520379A external-priority patent/GB0520379D0/en
Priority claimed from GB0520377A external-priority patent/GB0520377D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20070707A1 publication Critical patent/PE20070707A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE A ES A1, A2, A3, A4 Y A5; R1 ES ALQUILO C1-C18, ALQUENILO C2-C18, ALQUINILO C2-C18 SUSTITUIDO O NO POR ALCOXILO C1-C4, ARILO C6-C18, HETEROCICLILO, ENTRE OTROS; R2 ES CICLOALQUILO C3-C18, ARILO C3-C18, HETEROCICLILO; R3 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8 SUSTITUIDOS O NO POR CICLOALQUILO C3-C18, ARILO C3-C18, HETEROCICLILO; R4 ES (TRIALQUILO C1-C6)-SILILOXILO, N3, AMINO, ENTRE OTROS; R5 ES H, ALQUILO C1-C18, ALQUENILO C2-C18, ALQUINILO C2-C18 SUSTITUIDOS O NO POR ALCOXILO C1-C4, (TRIALQUILO C1-C6)-SILILOXILO, ENTRE OTROS; R6 ES OH, METOXI, O-PROPENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (6R,7aS)-1,6-DIHIDROXI-7a-METIL-2-FENIL-5,6,7,7a-TETRAHIDRO-PIRROLIZIN-3-ONA; (S)-7a-(4-CIANO-BENCIL)-6-(3,5-DICLORO-FENIL)-7-METOXI-5-OXO-2,3,5,7a-TETRAHIDRO-1H-PIRROLIZIN-2-IL-ESTER DEL ACIDO ACETICO; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE LFA-1 UTILES EN EL TRATAMIENTO DE CONDICIONES ALERGICAS, INFLAMATORIAS, ENFERMEDADES AUTOINMUNES, , RECHAZO DE TRASPLANTE, ENFERMEDADES ANTIPROLIFERATIVAS, ENTRE OTROS
PE2006001210A 2005-10-06 2006-10-04 Compuestos de tetrahidro-pirrolizinona como inhibidores de lfa-1 PE20070707A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0520376.5A GB0520376D0 (en) 2005-10-06 2005-10-06 Organic compounds
GB0520379A GB0520379D0 (en) 2005-10-06 2005-10-06 Organic compounds
GB0520377A GB0520377D0 (en) 2005-10-06 2005-10-06 Organic compounds

Publications (1)

Publication Number Publication Date
PE20070707A1 true PE20070707A1 (es) 2007-08-20

Family

ID=37507534

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001210A PE20070707A1 (es) 2005-10-06 2006-10-04 Compuestos de tetrahidro-pirrolizinona como inhibidores de lfa-1

Country Status (12)

Country Link
US (1) US20080262070A1 (es)
EP (1) EP1937685A1 (es)
JP (1) JP2009510150A (es)
KR (1) KR20080050605A (es)
AR (1) AR056207A1 (es)
AU (1) AU2006299017B2 (es)
BR (1) BRPI0616870A2 (es)
CA (1) CA2624488A1 (es)
GT (1) GT200600449A (es)
PE (1) PE20070707A1 (es)
TW (1) TW200800169A (es)
WO (1) WO2007039286A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
DE102010008644A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102011080405A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-8,8-difluor-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-one zur Therapie
JP2014508752A (ja) 2011-02-17 2014-04-10 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 治療用の置換3−(ビフェニル−3−イル)−8,8−ジフルオロ−4−ヒドロキシ−1−アザスピロ[4.5]デカ−3−エン−2−オン
DE102011080406A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro8[4.5]dec-3-en-2-one

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581462A (en) * 1983-08-25 1986-04-08 The Upjohn Company Pyrrolizidine-3-ones
ATE292634T1 (de) * 1999-10-20 2005-04-15 Tanabe Seiyaku Co Inhibitoren der alpha-l beta-2 vermittelten zelladhäsion
WO2002050080A1 (en) * 2000-12-19 2002-06-27 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
TW200303200A (en) * 2002-02-07 2003-09-01 Tanabe Seiyaku Co Inhibitors of α L β 2 integrin mediated cell adhesion
US20030232817A1 (en) * 2002-05-29 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful for the treatment of inflammatory disease
US7375237B2 (en) * 2004-08-18 2008-05-20 Bristol-Myers Squibb Company Pyrrolizine compounds useful as anti-inflammatory agents

Also Published As

Publication number Publication date
AU2006299017B2 (en) 2010-11-04
JP2009510150A (ja) 2009-03-12
BRPI0616870A2 (pt) 2011-07-05
CA2624488A1 (en) 2007-04-12
AR056207A1 (es) 2007-09-26
EP1937685A1 (en) 2008-07-02
US20080262070A1 (en) 2008-10-23
WO2007039286A1 (en) 2007-04-12
TW200800169A (en) 2008-01-01
GT200600449A (es) 2007-06-11
KR20080050605A (ko) 2008-06-09
AU2006299017A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
PE20070707A1 (es) Compuestos de tetrahidro-pirrolizinona como inhibidores de lfa-1
PE20120061A1 (es) Derivados de pirimidina como antagonistas del receptor ccr2
PE20110387A1 (es) Aminotriazolo-piridinas como inhibidores de cinasa
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20110924A1 (es) Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20080890A1 (es) DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES
PE20170679A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
PE20181048A1 (es) Amino triazoles sustituidos utiles como inhibidores de la quintinasa humana
PE20110409A1 (es) Compuestos heterociclicos antiviricos
PE20142164A1 (es) Inhibidores de diacilglicerol aciltransferasa 2
PE20121438A1 (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a
PE20080315A1 (es) DERIVADOS DE PIRAZOLO-[3,4-d]-PIRIMIDINAS COMO INHIBIDORES DE CINASA PI-3
PE20091492A1 (es) Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr
PE20200387A1 (es) Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer
MX358149B (es) Derivado de pirazoloquinolina.
PE20110383A1 (es) Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
PE20141588A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20130525A1 (es) Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
PE20090241A1 (es) Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
PE20080839A1 (es) Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA

Legal Events

Date Code Title Description
FC Refusal